NSAID gastropathy
Jump to navigation
Jump to search
Etiology
- non-steroidal anti inflammatory agents (NSAIDs)
- risk factors
- history of peptic ulcer
- high-dose NSAID use
- simultaneous use of multiple NSAIDs
- age > 60 years
- concomitant use of glucocorticoids
- anticoagulation
- tobacco use
- alcohol use
- protein malnutrition
- female sex
- concomitant cardiac disease
- concomitant H pylori infection*
* controversial
Epidemiology
- 5-10% of duodenal ulcers
- 20-40% as gastric ulcers
Pathology
Clinical manifestations
- dyspepsia
- NOT predictive of NSAID gastropathy
- many patients have no antecedent dyspepsia
- peptic ulcer disease (20%)*
- acute upper GI hemorrhage or perforation (1-2%)
* 20% of patients taking NSAIDs long-term will have endoscopic evidence of gastric or duodenal ulceration
Management
- proton-pump inhibitors (standard dose) 1st line[1]
- H2-receptor antagonists
- may decrease incidence of duodenal ulcers
- not effective for prevention of gastric ulcers*
- misoprostol
- treat concurrent H. pylori infection
- sucralfate of NO benefit[2]
- stopping NSAID may be indicated
- a COX-2 inhibitor may be useful
- if stopping anti-inflammatory agent is not an option, the most effective strategy to prevent recurrence is use of celecoxib plus twice daily proton pump inhibitor[1][5]
- restarting low-dose aspirin 3-5 days after upper GI bleed reduces 30-day mortality 10-fold in patients with cardiovascular disease, while increasing rebleeding rates only 2-fold[1]
* one study found famotidine effective in prevention of both duodenal & gastric ulcers in patients on long-term NSAID therapy
More general terms
Additional terms
References
- ↑ 1.0 1.1 1.2 1.3 Medical Knowledge Self Assessment Program (MKSAP) 11, 15, 16, 17. American College of Physicians, Philadelphia 1998, 2009, 2012, 2015
- ↑ 2.0 2.1 2.2 UCLA Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
- ↑ 3.0 3.1 Scheiman JM et al, Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors Am J Gastroenterol 2006; 1-1:701 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16494585
- ↑ 4.0 4.1 Luo J-C et al. Randomised clinical trial: Rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. Aliment Pharmacol Ther 2011 Sep; 34:519 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21726257
- ↑ 5.0 5.1 5.2 Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009 Mar;104(3):728-38 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19240698